Podcasts about leiomyosarcoma

Our latest interview with Dr Liz is the next Voice - the lovely and gentle human that is Astrid. Astrid shares how she has spent her entire adult life with major life changing health issues, which actually originally started from a childhood viral illness. Astrid had a childhood viral illness called Henoch Shonlein Purport which can be a simple uncomplicated illness, but in rare cases can cause kidney damage. For Astrid the HSP did cause kidney damage which went unnoticed. At 19 Astrid was diagnosed with high blood pressure but the underlying cause wasn't picked up on for several years by which point she had kidney failure, was started on renal dialysis and listed for an organ transplant. Astrid shares openly a very rare insight into the physical and emotional journey of being an organ donor recipient and how her donor lost her life but saved more than five others, and the result for Astrid meant she was then also able to go on and have children of her own. Not long after that investigation for a suspected fibroid actually identified a rare fallopian tube cancer - Leiomyosarcoma. A slow growing cancer which eventually spread to her spine and is now incurable.Astrid's pragmatic and philosophical approach to her health conditions shares a way of approaching life changing health conditions that is really profound and inspiring; how she refuses to be defined by her conditions and is fiercely determined to embrace life, continue to seek joy in things that bring her joy and focusing on the love for her family and sons. Astrid's mindset of being 'lucky in her unluckiness' is an example of how keeping focused on the positives and the present moment can have a profound impact on how one can come to terms with such major conditions. Thank you to Astrid for sharing her Scars Of Gold for this campaign.Scars of Gold is a health awareness campaign sharing the voices of 100 women facing their mortality at a young age with life changing or incurable health conditions. Produced by the charity @mortalandstrong (No. 1209448).#podcast #podcastprevious #interview #mortalandstrong #scarsofgold #kintsugi #hope #pov #dr #art #documentary #realvoices #cancer #leiomyosarcoma #sarcoma #secondarycancer #radiotherapy #kidneyfailure #hsp #hypertension #renalfailure #organtransplant #organdonor #renaltransplant #kidneytransplant #dialysis #mortal #womenshealth #healthmatters #healthadvocate #healthinequalities Hosted on Acast. See acast.com/privacy for more information.

Life is a series of adventures. Some that we choose and some that we don't. So how can we approach all of them with optimism, courage, and resilience?In this very special episode, Lucy is joined by her long-time friend Carol Mobley Rowe to discuss their many adventures — including stories of moving to Russia with their families and Carol's decade-long journey fighting and living with cancer, specifically Leiomyosarcoma.This is one of the most powerful and poignant conversations we've ever shared on the show, and we hope you'll tune in for Carol's encouragement to shoulder down and go for it, no matter the odds. Jump into the conversation:[6:30] Ways to seek adventure in midlife & beyond[8:00] How to balance your career & motherhood[11:00] Why Carol & her family chose to move abroad[12:30] Making big decisions with your spouse[15:45] Carol's cancer diagnosis[20:00] Learning to receive help[25:00] Carol's journey with Leiomyosarcoma[27:00] Advocating for ourselves and others[39:50] Carol's advice for her former self[44:00] What it takes to really cherish our memories More about our guest: Carol Mobley Rowe is a resilient and dynamic woman who seems to effortlessly manage a complex life with an extraordinary level of optimism and energy. She has juggled her own career while supporting her husband's rise through executive leadership, raised four grown kids while moving to countries around the world, and navigated herself through her own cancer journey over the past 10 years. Carol is currently living with Leiomyosarcoma. You can follow her journey @Carolsrarecancerjourney and support Leiomyosarcoma research by donating at this link. Stay connected:Check out The Murmuration CollectiveConnect with us on Instagram & LinkedInSubscribe to our monthly newsletter

LMS04 final OS results are published for doxorubicin + trabectedin in Leiomyosarcoma. Plus, a natural experiment of what happens in small cell lung cancer during an IV etoposide shortage. Finally, a nice paper provides some examples of how oncology pharmacists can bridge the care gap between oncology and primary care. LMS04: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2403394 IV etoposide shortage: https://doi.org/10.1200/OP.24.00394 Primary care - oncology pharmacy collaboration: https://doi.org/10.1177/10781552241279303

DermSurgery Digest at the Microscope dives deep into the latest dermatology literature exploring the latest techniques and diagnosis approaches. Each quarterly episode features interesting and relevant articles from Dermatologic Surgery, American Journal of Dermatopathology, Journal of Cutaneous Pathology, American Journal of Surgical Pathology and more.  This episode features articles on cutaneous and subcutaneous leiomyosarcoma.Contributors to this podcast include Naomi Lawrence, MD, Dermatologic Surgery Digital Content Editor; Ashley Elsensohn, MD, MPH, DermSurgery Digest At the Microscope co-host; Christine Ahn, MD; Jeff Gardner, MD; Marina K. Ibraheim, MD; and Michael P. Lee, MD.Articles featured include:Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous "leiomyosarcoma". Am J Surg Pathol. 2011 Apr;35(4):599-607. doi: 10.1097/PAS.0b013e31820e6093. PMID: 21358302.Kazlouskaya V, Lai YC, Khachemoune A. Leiomyosarcoma of the skin: review of the literature with an emphasis on prognosis and management. Int J Dermatol. 2020 Feb;59(2):165-172. doi: 10.1111/ijd.14705. Epub 2019 Nov 14. PMID: 31729020.Winchester DS, Hocker TL, Brewer JD, Baum CL, Hochwalt PC, Arpey CJ, Otley CC, Roenigk RK. Leiomyosarcoma of the skin: clinical, histopathologic, and prognostic factors that influence outcomes. J Am Acad Dermatol. 2014 Nov;71(5):919-25. doi: 10.1016/j.jaad.2014.07.020. Epub 2014 Aug 29. PMID: 25174541.Bresler SC, Gosnell HL, Ko JS, Angeles CV, Ronen S, Billings SD, Patel RM. Subcutaneous Leiomyosarcoma: An Aggressive Malignancy Portending a Significant Risk of Metastasis and Death. Am J Surg Pathol. 2023 Dec 1;47(12):1417-1424. doi: 10.1097/PAS.0000000000002126. Epub 2023 Sep 19. PMID: 37727934.Listeners are encouraged to submit questions for podcast hosts to answer in a later episode. To submit your questions, email communicationstaff@asds.net.

In this episode, we review the high-yield topic of ⁠⁠⁠⁠Leiomyosarcoma ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Pathology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Orthobullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on Social Media: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube --- Send in a voice message: https://podcasters.spotify.com/pod/show/orthobullets/message

In the summer of 2022, Luke Goodwin of the UK was driving his wife to work when he began experiencing a severe pain in his side and had to pull over and call for an ambulance, which didn't arrive for 8 hours. When he did make it to hospital he was originally diagnosed with kidney stones but, after tests were performed, he was told he had leiomyosarcoma—a rare type of cancer that grows in the smooth muscles. Doctors gave him 12 months to live. However, his use of cannabis oil is shrinking his tumors and he's winning his battle with the disease.

In last week's episode, Dr Rob Hermann shared a personal story about being diagnosed with a Leiomyosarcoma in his lower leg. I could have kept it in Ep 285 - Current State of Podiatric Surgery in Australia; however, it was a significant event in his life, and I didn't want it to be missed or overlooked, so I decided to edit it out of the original recording and create a separate mini-episode. I think you will enjoy it.  Podiatry Business Coaching  Hi, I'm Tyson Franklin, and if you're looking for a one-on-one podiatry business coach with a proven track record of helping podiatrists excel in business, look no further, I know I can help you.   If you'd like to talk, please email me at tf@tysonfranklin.com; otherwise, you can go directly to my online calendar to schedule a free 30-minute Zoom meeting. Whether you choose to work with me or not, you will leave our meeting with some strategic ideas to implement.  Upcoming LIVE Events If you're interested in attending one of my LIVE business events, details can be found at https://www.podiatrylegends.com/upcoming-events/ Podiatry Business Owner's Club Are you a podiatrist or podiatry student with an interest in business? If you are, all you need to do is answer three simple questions to join my Facebook Group – https://www.facebook.com/groups/podiatrybusinessownersclub. My YouTube Channel  Have you checked out my YouTube Channel – Tyson E Franklin? This is where I upload the  UNCUT videos of my interview podcast episodes and short educational videos.

Dr. George is a medical oncologist and Associate Professor at Harvard Medical School. She is the Clinical Director at the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute with over 20 years experience of treating patients throughout the world with sarcoma. She is actively involved in the clinical research and works to develop new clinical trials focusing on therapy for metastatic soft tissue sarcoma. In this episode we discuss: What led her into medicine, and what led her into taking care of patients with sarcoma - it included one of the first targeted therapies for a sarcoma subtype, GIST (Gastrointestinal Solid Tumor) What is Leiomyosarcoma including how is it treated, and challenges to the current treatment paradigm What is the Count Me In (CMI) Leiomyosarcoma (LMS) Project What the hope is to learn from CMI LMS How the CMI LMS project helps current and future people living with LMS What does Dr. George see as the next big thing for treating LMS   Here is the Link to the Count Me In Leiomyosarcoma Project music: Rosepigg photo:  nine koepfer 

Dr. Katie Janeway, a pediatric hematologist-oncologist of Dana Farber/Boston's Children Hospital, and Benjamin Zola, a Project Manager at Count Me In (CMI), will be joining to share more insight into Count Me In's patient- powered Osteosarcoma research project, and the potential outcomes for discoveries that can have a direct impact on the future osteosarcoma.  Count Me In (CMI) is a nonprofit research initiative on a mission to make every patient's experience count in the effort to understand and overcome cancer. Founded in 2018 by Emerson Collective,  Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute, Count Me In engages patients and enables them to accelerate cancer research by sharing their samples, clinical information, and voices. From their contributions, Count Me In analyzes and shares de-identified data freely to catalyze discoveries across cancer. Data generated by Count Me In is shared regularly via scientific platforms so that it can be harnessed by researchers everywhere to make impactful discoveries. All individuals living with cancer, including those from marginalized communities who have historically been excluded from research, no matter where they live, can contribute to breakthroughs and increase the pace of biomedical research. -- Dr. Katie Janeway received her medical degree from Harvard Medical School in 2000. She subsequently completed her residency in Pediatrics at Children's Hospital, Boston. She was a Chief Resident at Children's Hospital, Boston, and then completed her fellowship in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute / Children's Hospital, Boston. In 2007, Dr. Janeway joined the staff of Dana-Farber and Children's Hospital, Boston, where she is a pediatric hematologist-oncologist and investigator with a research focus of pediatric sarcomas. Ben Zola (he/him) is a Project Manager with Count Me In, a nonprofit research initiative that enables patients to accelerate cancer research by sharing their samples, their clinical information, and their voices. Ben has been with the team for over 2 years, and specifically manages Count Me In's projects in Osteosarcoma (osproject.org) and Leiomyosarcoma (lmsproject.org). Ben has a Bachelors Degree from Rutgers University in Biomedical Engineering, with a minor in Psychology. In his free time, Ben is a fitness instructor and also enjoys being outside and taking pictures of nature. ---- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Dr. Refky Nicola discusses the consensus statement on MRI assessment of uterine masses and features associated with leiomyosarcoma with Dr. Nicole Hindman. MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma: A Consensus Statement. Hindman et al. Radiology 2023; 306(2):e211658.

Uterine leiomyosarcoma is the most common uterine mesenchymal malignancy. The majority present at stage I with variable clinical outcome.In this episode of ModPath Chat, Dr. David Chapel discusses his recently published multi-institutional study proposing a novel risk stratification model (shown below) for low stage uterine leiomyosarcoma.Risk score = (coagulative necrosis)(1) + (mitoses > 25 per 2.4mm2)(2) + (atypical mitoses)(2) + (lymphovascular invasion)(3) + (serosal abutment)(5) See acast.com/privacy for privacy and opt-out information.

In this episode, we review the high-yield topic of Leiomyosarcoma from the Pathology section. Follow Orthobullets on Social Media: Facebook: www.facebook.com/orthobullets Instagram: www.instagram.com/orthobulletsofficial Twitter: www.twitter.com/orthobullets LinkedIn: www.linkedin.com/company/27125689 YouTube: www.youtube.com/channel/UCMZSlD9OhkFG2t25oM14FvQ --- Send in a voice message: https://anchor.fm/orthobullets/message

This episode covers sarcoma.Written notes can be found at https://zerotofinals.com/surgery/orthopaedics/sarcoma/ or in the orthopaedic section of the Zero to Finals surgery book.The audio in the episode was expertly edited by Harry Watchman.

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.Presenters:Jean-Yves Blay, MD, PhDProfessor of Medical OncologyDepartment of MedicineCentre Leon BerardLyon, FranceRobin L. Jones, BSc, MBBS, MRCP, MD(Res)ProfessorSarcoma UnitRoyal Marsden Hospital and Institute of Cancer ResearchLondon, United KingdomLink to full program, including accompanying downloadable slidesets:https://bit.ly/2ZL9bxq

On this episode of "Behind Diagnoses: Patients", a Peer Med Podcast special series we hear from Dafina Malovska, who was diagnosed with a gluten disorder when she really had Uterine Cancer. The only option to save her life was to have a total hysterectomy which meant the removal of her uterus and both ovaries. Womb cancer deprived her of having her own children. and placed her into immediate surgical menopause after the operation.  Now, she's become a powerful patient advocate that wants to change the face of healthcare in order to ensure more and greater access for care, screening, follow up and more for Female-Assigned at Birth people in the United Kingdom.  Be sure to subscribe to the Peer Med Podcast on Apple Podcasts, Spotify, Overcast, or wherever you get your podcasts! Follow the Peer  Med Podcast on Instagram @peermedpodcast for more patient stories, disease and inspiring eye-opening content!  Follow Dafina on Instagram: @dafimalov and sign her petition at https://www.change.org/checkMEupUK.  #checkmeup #peermedpodcast  

Oncotarget's cover paper this week (Volume 12, Issue 16) is entitled, "Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma," by researchers from Yale University School of Medicine, New Haven, CT. “In this study, we performed a comprehensive analysis and compared the DNA methylation and RNA expression profiles of ULMS and STLMS samples from the TCGA-SARC study.” First, the team identified two LMS subtypes based on their site of origin: uterine LMS (ULMS) and non-uterine soft tissue LMS (STLMS). Next, they compared their molecular landscapes using The Cancer Genome Atlas-Sarcoma (TCGA-SARC) dataset and comprehensively analyzed 27 ULMS and 53 STLMS samples. Researchers assessed for epigenetic and transcriptomic differences between ULMS and STLMS. They hoped these differences would help identify differentially methylated genes and differentially expressed genes (DEGs) in these LMS subtypes. Findings from the TCGA-SARC dataset were then compared to two independent DNA methylation datasets, GSE140686 and GSE68312. “In this study, we performed an integrated analysis of 98 clinically derived LMS samples and 11 controls using three publicly available datasets to identify epigenetic changes which characterize LMS subtypes and may be used as clinical biomarkers and therapeutic targets.” Datasets were then used in comparative DNA methylation analysis to compare controls with the identified epigenetic changes associated with tumorigenesis. Network and pathway analysis were performed to further characterize the differential transcription signatures between ULMS and STLMS. Full blog - https://www.oncotarget.org/2021/08/04/epigenetic-signatures-differentiate-leiomyosarcoma-subtypes/ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28032 DOI - https://doi.org/10.18632/oncotarget.28032 Full text - https://www.oncotarget.com/article/28032/text/ Correspondence to - Nita Ahuja - nita.ahuja@yale.edu Keywords - leiomyosarcoma, epigenetics, DNA methylation, gene expression, uterine leiomyosarcoma About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Today Ashley opens up about losing both of her parents to cancer. Her mom died of Leiomyosarcoma and her dad died of Appendiceal cancer both within the past 6 years when Ashley was in her late 20s. We also discuss her dog's cancer treatments & she shares what it has been like to start your own company during a pandemic.  Ashley Marie, a serial snacker since birth, is the Founder & Chief Snack Officer of B.T.R. Bar. Ashley started the company in honor of her parents, determined to pass on their legacy and inspire the world to be BOLD, TENACIOUS & RESILIENT. As their caretaker, working full-time, Ashley was constantly on-the-go, inhaling so-called "better-for-you" bars and bites high in sugar with ingredients she couldn't pronounce. With a background in nutrition & food studies, Ashley craved a snack with a "BTR" ingredient profile that also served a functional purpose. And that's how B.T.R. Bar was born. @btr.bar Use code LAUGHTER10 for 10% off site wide: https://www.eatbtrbar.com/discount/LAUGHTER10 Say hi! @dyingoflaughter_podcast DyingOfLaughterPodcast@gmail.com Do you like this show? Leaving a review on Apple Podcasts is extremely appreciated...I read & cherish every single one! Thank you so much for being here!

Kamesh Vadlamani, caregiver of his aunt who had Leiomyosarcoma, tells us why keeping cancer patients happy is a very important role in a caregiver's life. ZenOnco.io - Making quality integrative oncology cancer care accessible to all. If you or your loved one has been diagnosed with cancer recently, and need guidance on treatment or have any doubts or queries, please call ZenOnco.io on +91 99 30 70 90 00.

Episode 2.8 Kate Leipprandt shares her story of being diagnosed with Leiomyosarcoma after the removal of a 10 pound tumor.

Guest: Julie Rohr, Edmonton Resident, surviving stage 4 Leiomyosarcoma.

What do you do when you’re diagnosed with a rare form of Leiomyosarcoma at the tender age of 33? When your world is tipped upside down and the odds are stacked against you, how do you cope? This episode is a brilliantly hopeful conversation with Julie Rohr — cancer fighter and intentional optimist. The post Julie Rohr – The Power of Perspective (#006) appeared first on Confronting Normal.

Dr Schöffski presents, at a press conference at ASCO 2015, findings from a randomised phase III trial point to a promising new therapy for patients with advanced intermediate or high grade liposarcoma or leiomyosarcoma whose disease worsened after two or more lines of initial therapies.

Dr Schwartz gives an expert commentary on data presented at ASCO 2015. 452 patients with advanced leiomyosarcoma or adipocytic sarcoma, which is also called liposarcoma, were randomly assigned to treatment with eribulin or dacarbazine until disease progression. The median overall survival was 13.5 months in the eribulin group and 11.5 months in the dacarbazine group. Dr Schwartz looks at the implications of this and gives some background on the difficulty of treating sarcomas.

Dr Schöffski talks to ecancertv at ASCO 2015 about the findings of a randomised phase III trial that point to eribulin as a promising new therapy for patients with advanced intermediate or high grade liposarcoma or leiomyosarcoma whose disease worsened after two or more lines of initial therapies.

A truely unique story about how Donald Rutledge met death. A vision so vivid that it dictated the course of the rest of his life. Listen to see how he faced his cancer, Leiomyosarcoma, and how the power of prayer rippled throughout his life. 

This is the first in a series of audio podcasts about Leiomyosarcoma. Guest: Dr. Vinod Ravi of The University of Texas MD Anderson Cancer Center's Sarcoma Center.

Guest: John Brooks, MD Host: Mark Nolan Hill, MD Because sarcomas only account for a small percentage of new cancer cases, tissue samples for research purposes are not so easy to obtain. In this segment, learn from Dr. John Brooks how the LMS foundation started a tissue bank to help gather leiomyosarcoma tissue for research.